key: cord-0829654-rb56nd63
authors: Files, J. K.; Boppana, S.; Perez, M. D.; Sarkar, S.; Lowman, K. E.; Qin, K.; Sterrett, S.; Carlin, E.; Bansal, A.; Sabbaj, S.; Long, D. M.; Kutsch, O.; Kobie, J.; Goepfert, P. A.; Erdmann, N.
title: Sustained Cellular Immune Dysregulation in Individuals Recovering from SARS-CoV-2 Infection
date: 2020-08-01
journal: nan
DOI: 10.1101/2020.07.30.20165175
sha: 5db99dbe579c42a2db906f7cd58c940c430eb3fa
doc_id: 829654
cord_uid: rb56nd63

SARS-CoV-2 causes a wide spectrum of clinical manifestations and significant mortality. Studies investigating underlying immune characteristics are needed to understand disease pathogenesis and inform vaccine design. In this study, we examined immune cell subsets in hospitalized and non-hospitalized individuals. In hospitalized patients, many adaptive and innate immune cells were decreased in frequency compared to healthy and convalescent individuals, with the exception of B lymphocytes which increased. Our findings show increased frequencies of T-cell activation markers (CD69, Ox40, HLA-DR and CD154) in hospitalized patients, with other T-cell activation/exhaustion markers (CD25, PD-L1 and TIGIT) remaining elevated in hospitalized and non-hospitalized individuals. B cells had a similar pattern of activation/exhaustion, with increased frequency of CD69 and CD95 during hospitalization, followed by an increase in PD1 frequencies in non-hospitalized individuals. Interestingly, many of these changes were found to increase over time in non-hospitalized longitudinal samples, suggesting a prolonged period of immune dysregulation following SARS-CoV-2 infection. Changes in T-cell activation/exhaustion in non-hospitalized patients were found to positively correlate with age. Severely infected individuals had increased expression of activation and exhaustion markers. These data suggest a prolonged period of immune dysregulation following SARS-CoV-2 infection highlighting the need for additional studies investigating immune dysregulation in convalescent individuals.

Since the first reports in December 2019, Coronavirus Disease 2019 , caused by the novel virus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has spread worldwide and caused enormous public health and economic impacts (1, 2) . Many patients remain asymptomatic or have mild symptoms (3) , while others, particularly those with comorbidities, develop severe clinical diseases with atypical pneumonia and multiple system organ failure (4) (5) (6) . To date, there have been over 16 million reported cases with 645,000 COVID-19 related deaths (7) , and with no imminent vaccine, understanding of the immune pathology associated with patients of various clinical outcomes is urgently needed.

Several early studies have shown that acutely infected individuals develop lymphopenia (4, (8) (9) (10) (11) and exhibit elevated expression of T-cell activation markers (12) (13) (14) . Additionally, several groups have shown differential expression of T-cell exhaustion markers between severe and mild clinical cases (12, 13, 15) . Studies have reported increased NKG2A levels in both CD8+ T cells and NK cells that return to baseline in convalescence (13) , and increased monocyte frequencies in comparison to lymphocytes when using single-cell RNA sequencing analysis (16) ; however, these studies were limited in scope. Recent reports have described the presence of SARS-CoV-2-specific T cells in convalescent patients (17, 18) , emphasizing the value of studying immune subsets in convalescent individuals who have recently overcome infection in order to better inform vaccine and therapeutic efforts.

SARS-CoV-2 (24, 25) and more recent large cohort studies have described immune perturbations in acutely infected hospitalized individuals with severe infection (26, 27) . In acute viral infections such as influenza, several groups have shown evidence of prolonged immune activation during the convalescent phase that correlated with worse clinical outcomes (28) (29) (30) . Studies investigating antibody responses in MERS were found to be undetectable in patients who had mild illness following infection (31) . These findings highlight the need for studies investigating the immune system of both hospitalized and non-hospitalized SARS-CoV-2 individuals. Here, we evaluate immune cell subsets of SARS-CoV-2 infected individuals and identified dysregulated immune cells in both hospitalized and non-hospitalized individuals over time.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07. 30.20165175 doi: medRxiv preprint

Others previously described that SARS-CoV-2 infected individuals, especially those with severe infection, have pronounced lymphopenia compared to healthy and convalescent individuals (4, 8, 9) . However, most of these studies were done in hospitalized patients and only evaluated a few cell types. Here, we obtained samples and clinical data from a cohort of hospitalized COVID-19 patients ("Hospitalized", n=46) and a cohort of non-hospitalized individuals who had recovered from confirmed COVID-19 infection ("Non-hospitalized", n=39).

These groups were compared to healthy, COVID-19 negative controls ("Healthy", n=20). An overview of the cohort demographics is shown in Table 1 . Importantly, most individuals in the hospitalized group (n=36) were viremic and hospitalized at the time of sample collection; however, a minority (10 of 46) were asymptomatic for at least 3 consecutive days and were at least 7 days past initial diagnosis at the time of initial sample collection and therefore could be classified as convalescent, but were still included in the hospitalized group due to disease severity. All individuals in the non-hospitalized group were convalescent at the time of sample collection. As shown in Table 1 , there were differences between age, race, and comorbidities.

Many of these differences reflect the nature of the COVID-19 pandemic, with more severe infection being associated with older age, African-American race, and those with pre-existing comorbidities.

As previously described (32) , we found that hospitalized individuals in our study displayed normal WBC counts but distinctly lower numbers of lymphocytes ( Table 1) . To further assess immune cells that remain during SARS-CoV-2 infection, we utilized a general . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint immunophenotyping flow cytometry panel to evaluate the proportion of specific immune cell subsets within the total CD45+ cell population in each individual (overview shown in Figure 1A) .

While there was a decrease in the lymphocyte counts, we observed no significant decrease in proportion of CD4+ T cells in the total CD45+ population ( Figure 1B) . There was an increase in CD8+ T cell frequencies in the non-hospitalized group compared to the hospitalized group ( Figure   1C , p=0.003). In contrast, B-cell frequencies were decreased in non-hospitalized individuals in comparison to our healthy and hospitalized groups (Figure 1D , p=0.002 and p<0.001, respectively).

We investigated the innate immune cell subsets including NK T cells, NK cells, monocytes, and dendritic cells, which have been shown to play a protective role during other acute viral infections, including influenza A (33) . Interestingly, many of these subsets showed decreased frequencies in hospitalized patients and returned to baseline in non-hospitalized individuals.

There was a trend towards decreased NK T cells in the hospitalized group compared to healthy and non-hospitalized ( Figure 1E , p=0.057 and p=0.057, respectively). Similarly, hospitalized individuals had decreased double positive (DP) CD56+CD16+ NK cells ( Figure 1F , compared to healthy: p=0.023 and compared to non-hospitalized: p=0.011) and CD56+CD16-NK cells ( Figure   1G , compared to non-hospitalized: p=0.009). There were decreased frequencies of CD14+ monocytes in hospitalized individuals when compared to healthy and non-hospitalized ( Figure  6 decreased in both our hospitalized and non-hospitalized samples were decreased as compared to healthy (Figure 1K , p=0.003 and p=0.007 respectively). These data show altered immune cell frequencies in hospitalized individuals, and while some of these observed perturbances are missing in the non-hospitalized individuals, decreased frequencies of DP monocytes and dendritic cells suggest a degree of sustained immune dysfunction in both groups of SARS-CoV-2-infected individuals.

Prior findings suggest that T cells upregulate activation and exhaustion markers during acute COVID-19 infection, especially in severe infection (12-15, 26, 27) . Here, we examine T-cell phenotypes in infection and convalescence, separating our cohort based on severity of infection into individuals who were hospitalized and non-hospitalized. We measured surface-level expression of the activation markers CD69, Ox40, CD38, CD137, and CD154. We also analyzed the T-cell exhaustion markers TIGIT, PDL1, PD1 and Tim3. Notably, PD1 and Tim3, while often classified as exhaustion markers, have also been shown to be activated during other acute infections (34, 35). Finally, we stained for CD27 and CD28 as loss of these markers has been found to represent a loss of differentiated memory T cells, suggesting a more senescent phenotype (36).

An overview of the relative frequencies of all cell markers within CD4+ T cells are shown in the heatmap in Supplemental Figure 1A . In hospitalized individuals, we observed elevated frequencies over healthy and non-hospitalized groups with respect to CD69 (Figure 2A , p<0.001 and p<0.001, respectively), Ox40 (Figure 2B , p<0.001 and p<0.001, respectively) and PD1 ( Figure   2C , p<0.001 and p=0.005, respectively). The markers HLA-DR, CD154, and Tim3 were elevated in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint hospitalized over non-hospitalized individuals (Figures 2D-2F , p=0.009, p=0.028 and p=0.047, respectively). Collectively, these observations identify markers elevated during severe infection, but then return to baseline with resolution of symptoms or remain normal in mild infection. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint respectively). Overall, expression of these activation and exhaustion markers indicates more severe immune dysregulation of CD8+ T cells in the hospitalized group.

To help characterize the B lymphocyte population in this cohort, we looked at the activation markers CD69, CD95, and HLA-DR. Fc receptor-like 4 (FcRL4) was also measured, as it is upregulated on B cells of lymphoid tissue, increased in the periphery during some chronic infections and autoimmune diseases, and is associated with an exhausted B-cell phenotype (37-42). We also examined the frequencies of the exhaustion marker PD1, and the memory marker, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint We next performed longitudinal analyses comparing the expression of activation and exhaustion markers over time. We did this in two ways: 1) observing changes in marker frequencies over time, defined as days post-symptom onset (median = 29 days; range 19-40), utilizing all non-hospitalized samples with a recorded date post-symptom onset (n=23); and 2) directly comparing the frequencies of these markers between Visit 1 and Visit 2 for those nonhospitalized patients with samples collected at two sequential timepoints (n=25).

Interestingly, when investigating changes in activation and exhaustion markers we . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint Other activation markers also had an increased frequency at the later timepoint, including CD69 and CD154 (Supplemental Figure 2C -D, p<0.001 and p=0.007 respectively). Additionally, we found that CD8 T-cell expression of exhaustion markers increased in non-hospitalized individuals over time when looking at days post-symptom onset and visit 1/visit 2 analyses for TIGIT and PDL1 ( Figure 6B and 6C, p=0.006, p=0.003, p=0.051 and p=0.009, respectively), as well as Tim3 (Supplemental Figure 2E , p=0.036). We also observed significantly decreased frequencies of CD27 and CD28 based on days post-symptom onset and visit 1/visit 2 analyses, albeit with low correlation coefficients ( Figure 6D and 6E, p=0.039, p=0.014, p=0.035 and p=0.009, respectively).

In summary, we show that the frequency of several activation and exhaustion markers in CD8+ T cells may initially be lower in non-hospitalized individuals in comparison to the hospitalized group; surprisingly, many of these markers appear to increase over time in the convalescent phase in these individuals. Figure 3D and 3E, p<0.001 and p=0.005, respectively). Overall, these data begin to suggest that the B cell population remains activated in non-hospitalized patients well into the convalescent period.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint

Since older SARS-CoV-2 patients have higher morbidity and mortality rates (43), we investigated differences related to age in each of our groups. By analyzing samples at the visit 1 timepoint in the hospitalized group, we found a positive correlation between age and CD8+ Tcell expression of CD69 (Supplemental Figure 4A , p=0.009), as well as a negative correlation between age and CD8 expression of CD27 and CD28 (Supplemental Figure 4B and 4C, p=0.010 and p=0.003, respectively). We observed a positive correlation between age and frequencies of CD69, CD95, and FcRL4 within the B-cell population of our hospitalized individuals (Supplemental Figure 4D-4F; p=0.024, p=0.024, and p=0.014, respectively). Analysis of CD4+ T cells and age in hospitalized individuals had no significant findings. We observed no differences between age and marker frequencies in healthy controls across all subsets.

We next investigated any correlations of age and frequency of activation and exhaustion markers in the non-hospitalized group. Our group and others have reported that elderly individuals form suboptimal immune responses following vaccination and infection (44). In this study, within the CD4+ T-cell compartment, we observed increased frequencies of PD1, TIGIT, and HLA-DR that correlated positively with age ( Figure 7A -C, p=0.002, p=0.032 and p=0.022, respectively). We also observed a loss of CD28 expression in elderly individuals (Figure 7D, p=0.027). Similarly, in our CD8+ T-cells, there were increased PD1, HLA-DR, and TIGIT frequencies that correlated positively with age ( Figure 7E-7G, p<0 .001, p=0.007, and p=0.008, respectively), while expression of CD27 and CD28 had a negative correlation with age ( Figure 7H and 7I, p<0.001 and p=0.010, respectively). Finally, there was a decrease in CD27+ B cells with age (data . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint not shown, p=0.007). Of note, T cell and B cell expression of CD27 and CD28 has been shown to decline in the elderly by several groups (45). While more in-depth studies investigating T-cell function with age in SARS-CoV-2 infected individuals are necessary, these data found that T-cell immune dysregulation following SARS-CoV-2 infection is more pronounced in older nonhospitalized patients, suggesting that older individuals may have an impaired ability to form SARS-CoV-2-specific memory responses.

Finally, we evaluated whether severity of illness impacted expression of activation and exhaustion markers within our hospitalized group as several other reports have found increased expression of activation/exhaustion markers in severe infection (12-15, 26, 27) . We stratified samples from our hospitalized group into two groups: ICU (n=26) and non-ICU patients (n=10).

(Note: 10 samples from the hospitalized group were collected in the convalescent period and thus were excluded in this analysis.) Our analysis found that ICU patients had increased CD69 expression on CD4+ T cells (Figure 8A , p=0.004), and CD38 frequencies were elevated in both CD4+ and CD8+ T cells (Figures 8B and 8C , p=0.049 and p=0.025, respectively), similar to recent results (12-15, 26, 27) . In addition, the exhaustion marker PDL1 was found to be elevated in ICU patients (Figure 8D, p=0.018) . Interestingly, the marker CD137 was found to be decreased in frequency in ICU patients (Figure 8E , p=0.002). Of note, CD137 has been found to play an important role in acute infection within mice (46). B cells from ICU patients had a trending increase in CD95 frequencies, significant increase in CD27 frequencies, while having decreased expression of HLA-DR (Figures 8F-8H , p=0.055, p=0.029, and p=0.045, respectively). In summary, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint 13 these findings better define the dysfunctional immune response observed in severe SARS-CoV-2 infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint

Here we provide a comprehensive look at immune cell subsets during and after COVID-19 infection of hospitalized and non-hospitalized individuals. We found dysregulation of several immune cell types in hospitalized patients, whereas most had returned to baseline in nonhospitalized individuals. We also provide an in-depth characterization of the activation and exhaustion phenotype of CD4+ T cells, CD8+ T cells and B cells. While we observed activation marker upregulation in hospitalized patients, we also found several activation and exhaustion markers were expressed at higher frequencies in non-hospitalized convalescent samples. When investigating these markers, we observed several positive relationships over time, indicating that immune dysregulation in these individuals does not resolve quickly. We also found the dysregulation of T-cell activation and exhaustion markers in non-hospitalized individuals appears more pronounced in the elderly. To our knowledge, this is the first description of sustained immune dysregulation due to COVID-19 in a large group of non-hospitalized convalescent patients. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . represent an impaired ability to form memory T cells. This is supported by prior observations on IL-10 production in SARS and SARS-CoV-2 individuals where IL-10 production by regulatory CD4+

T cells was shown to be necessary for memory CD8+ T cell development in mice (53). In SARS patients, there was shown to been an increase in IL-10 production during the convalescent phase of infection (54); however, a recent report on SARS-CoV-2 infected individuals has found that serum levels of IL-10 were highest during acute infection and decreased in convalescence (15) . How this dysregulation relates to SARS-CoV-2 antibody responses is unknown.

The finding of more pronounced T-cell activation/exhaustion in elderly non-hospitalized SARS-CoV-2 individuals has many potential implications. In acute disease, these findings suggest this group may be at heightened risk for inflammation-mediated pathology. This immune dysfunction may also lead to suboptimal SARS-CoV-2-specific memory responses and increased susceptibility of re-infection. Additional longitudinal studies are needed to better understand the impact of T-cell activation on long term immunity.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. We extended our analysis to separate hospitalized patients that did or did not require intensive care. This revealed several differences in surface markers on T and B cell populations.

Not surprisingly, activation markers were more frequently observed in severely infected individuals, in support of recent observations on the expression of HLA-DR and CD38 (26, 27).

Our findings are the first report of upregulated PDL1 in severe COVID-19 patients. Interestingly, we observed that non-ICU patients had increased expression of CD137. Prior studies observed that CD137 can augment immune responses in acute viral infections, and that blocking CD137 Our current study has a few limitations. For one, our immunophenotyping panel prioritizes the identification of some subsets such as lymphocytes and monocytes over others, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint primarily dendritic cells. Although a marker for CD11c would have increased our ability to identify this population, we believe our gating strategy (CD3-CD19-CD14-CD56-CD16-HLADRhi) still identifies a relatively pure population of dendritic cells. Additionally, we acknowledge that there are substantial differences in age, race and sex between our hospitalized, non-hospitalized and healthy groups as summarized in Table 1 . These differences reflect the nature of the COVID-19 pandemic, with numerous sources reporting increased hospitalizations and more severe clinical symptoms in elderly and African-American populations. We have controlled for this by performing general linear models comparing hospitalized, non-hospitalized, and healthy groups in pairwise models that have each been adjusted for participant age, race, and sex. Results are summarized in Supplementary Tables 1-3 . This analysis shows that a majority of the significant relationships as determined by Wilcoxon analysis remain significant after adjusting for age, race and sex. In the remaining relationships that were not significant by hospitalization status, there were also no significant findings to support that these relationships were driven by age, race, or sex. One exception to this was the finding that the decrease in CD16+ monocytes in our hospitalized group appears to be driven by sex (Supplemental Table 1 ). In addition, our hospitalized group had an increased frequency of existing comorbidities (shown in Table 1 ). This was expected since many of these risk factors have been found to correlate with worsening clinical outcomes in COVID-19 infection. Our study provides important insights into acute and subacute COVID-19 immune responses but leaves questions unanswered in relation to comorbidities and their impact on immunophenotyping. Future studies using larger cohorts should directly examine the potential impact of these comorbidities on immune cell dysregulation in COVID-19 infection.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. Table 1 . Peripheral blood mononuclear cells (PBMCs) from patient blood samples were harvested using density gradient centrifugation.

Additionally, our cohort of healthy (CoV-) individuals were comprised of 20 total samples. Of these, frozen PBMCs (n=17) from before 2019 were used primarily to ensure the absence of asymptomatic SARS-CoV-2 infections; additionally, fresh samples were collected from three asymptomatic seronegative individuals, and analysis from each of these samples showed no significant differences between fresh and frozen samples within that individual.

Flow Cytometric Analyses: Isolated PBMCs were stained using one of four different phenotyping panels (Supplemental Table 4 ). Immune cell subsets were identified with the following immunophenotyping panel: CD16-FITC, CD14-A700, CD45-Pecy7, CD19-Percpcy5.5, CD27-PEAlexa610, CD56-BV421, CD3-A780, CD8-V500, CD4-BV785, and HLADR-PE. T cells were further characterized using two additional panels: (1) CD8-V500, CD3-BV711, CD4-BV786, CD38-BUV737, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. 

Statistics: All statistical analysis and figure generation was performed using R. Significance between groups was performed using Wilcoxon rank sum test (unpaired) or Wilcoxon signed rank test (paired). Significance between two continuous variables was calculated by using a Spearman's correlation test or a mixed effect model in order to account for convalescent individuals with multiple time points. Additionally, linear modeling was used to verify significant relationships between different hospitalization groups were not driven by differences in age, race, or sex.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint to acknowledge Anisha Jackson and Ainsley Greenstein for help in obtaining clinical data.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 1, 2020. . https://doi.org/10.1101/2020.07.30.20165175 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical and immunological features of severe and moderate coronavirus disease 2019

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

A Dynamic Immune Response Shapes COVID-19 Progression

Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19)

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

Comprehensive mapping of immune perturbations associated with severe COVID-19

Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease

Prolonged Activation of Virus-Specific CD8T Cells after Acute B19 Infection

Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study

MERS-CoV Antibody Responses 1 Year after Symptom Onset

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

We would first like to thank all patients for giving consent for sample collection for this study.Additionally, we want to thank the clinical collection and UAB CFAR biorepository teams for their assistance in sample collection, as well as the hospital staff for their dedication in fighting coronavirus. We would like to acknowledge Lynn Pritchard, Tim Fram, and David Moylan who all processed several PBMC samples used in this project, as well as the UAB CFAR Basic Research Core (P30 AI027767-31) for use of flow cytometer and BSL2+ facility. Finally, we would also like